ArticleSAGE open medicine2025
A mixed-effect model for the evolution of unbalanced longitudinal hematocrit levels in chronic kidney failure patients.
Article in SAGE open medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease, or renal failure, is a public health problem with an estimated prevalence of 8%-16% worldwide. This study was conducted to investigate the evolution of hematocrit levels over time in renal patients after transplantation and to determine how the evolution of hematocrit levels depends on the patients' age, sex, and other factors. Objective: The main objective of this study was to employ a mixed-effects model to examine the unbalanced longitudinal evolution of hematocrit levels in chronic kidney failure patients. Methodology: This longitudinal study included 1160 patients who received a renal transplant. These patients were followed for at most 10 years. The hematocrit level was considered the response, while the covariates were time in years, sex, and age of the patients. Different statistical methods, such as explanatory analysis, multivariate regression, two-stage analysis, and linear mixed-effects models, were employed to explore the evolution of hematocrit over time. Results: The results revealed that hematocrit levels in kidney transplant patients evolve. The sex and age of the patient significantly affect the evolution of hematocrit levels. Males tend to have a greater increase in hematocrit levels over time than females do. Hematocrit levels tend to increase with increasing age. Furthermore, cardiovascular problems before transplant and rejection symptoms did not significantly affect the evolution of hematocrit levels. Conclusions: Hematocrit levels evolve, and this evolution follows a quartic time effect. The change in hematocrit levels varies according to the sex and age of the patient after a kidney transplant. Patients with low hematocrit levels tend to have a greater increase over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.